ArticleAntimicrobial agents and chemotherapy2007
Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis.
Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Dynamic distribution of systemically administered antibiotics in orthopeadically relevant target tissues and settings.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2024Pooled it
- Penetration of Antibiotics into Subcutaneous and Intramuscular Interstitial Fluid: A Meta-Analysis of Microdialysis Studies in Adults.Clinical pharmacokinetics · 2024Pooled it
- Pharmacokinetics of the local anesthetic ropivacaine after transversus abdominis plane block in healthy volunteers.European journal of clinical pharmacology · 2012Trial
- Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection.Antimicrobial agents and chemotherapy · 2010Trial
- Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration.Antimicrobial agents and chemotherapy · 2009Trial
- Impact of clarithromycin on monocytes-macrophages in patients with coronary arterial disease: a crucial study in cardiovascular research.Molecular biology reports · 2026Article
- Intravenous Clarithromycin in Critically Ill Adults: A Population Pharmacokinetic Study.Antibiotics (Basel, Switzerland) · 2025Article
- Advanced drug delivery and therapeutic strategies for tuberculosis treatment.Journal of nanobiotechnology · 2023Review
- Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses.The Journal of antimicrobial chemotherapy · 2022Article
- Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2015Article
- A comprehensive review on the pharmacokinetics of antibiotics in interstitial fluid spaces in humans: implications on dosing and clinical pharmacokinetic monitoring.Clinical pharmacokinetics · 2014Review
- Role of microdialysis in pharmacokinetics and pharmacodynamics: current status and future directions.Clinical pharmacokinetics · 2014Review
- Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments.Therapeutic advances in infectious disease · 2014Article
- Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.Clinical microbiology reviews · 2013Review
- Pilot investigation on long-term subcutaneous microdialysis: proof of principle in humans.The AAPS journal · 2013Article
- Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy.Antimicrobial agents and chemotherapy · 2012Article
- Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis.Current clinical pharmacology · 2010Review
- Protein binding of antimicrobials: methods for quantification and for investigation of its impact on bacterial killing.The AAPS journal · 2009Review
- Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.Clinical pharmacokinetics · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antimicrobial spectrum of clarithromycin renders this antibiotic a frequently used option in the treatment of skin and soft-tissue infections. In most cases, these infections are caused by extracellularly proliferating microorganisms. Thus, clarithromycin concentrations achieved in the interstitial space are considered particularly important for clinical efficacy. In the present study, clarithromycin concentrations in plasma and interstitial-space fluid of subcutaneous adipose tissue and skeletal muscle of six healthy male volunteers were assessed by means of the microdialysis technique after oral single-dose administration of 250 mg and multiple doses of 500 mg of clarithromycin twice a day (b.i.d.). The ratios of the area under the concentration-time curve of free clarithromycin from 0 to 24 h calculated for a single dose of 250 mg (fAUC(0-24)) in interstitial-space fluid to the fAUC(0-24) in plasma were 0.29 +/- 0.17 and 0.42 +/- 0.18 for subcutis and skeletal muscle, respectively. For 500 mg of clarithromycin at the steady state (3 to 5 days of intake twice daily), the fAUC(0-24(b.i.d.)) ratios at the steady state were 0.39 +/- 0.04 and 0.41 +/- 0.19 for subcutis and skeletal muscle, respectively. The half-life was around 2 h after a single dose but increased to approximately 4 h in plasma and tissues after repetitive clarithromycin administration. Based on subsequently performed pharmacokinetic-pharmacodynamic calculations, a dosing regimen of 500 mg b.i.d. may be ineffective in the treatment of soft-tissue infections caused by pathogens with a drug MIC higher than 0.125 mg/liter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.